Division of Nephrology and Hypertension, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Hypertension. 2010 Jun;55(6):1381-8. doi: 10.1161/HYPERTENSIONAHA.110.150995. Epub 2010 Apr 5.
The transcription factor ETS-1 is a critical mediator of vascular inflammation and hypertrophy in hypertension. We tested the hypothesis that ETS-1 is a mediator of proinflammatory responses and neointimal hyperplasia after balloon injury of the carotid artery. For this study, we took advantage of the availability of an ETS-1 dominant-negative (DN) peptide. Sprague-Dawley rats were assigned to treatment with ETS-1 DN, a mutant peptide (ETS-1 MU), or vehicle (Veh) and subjected to balloon injury of the carotid artery. After 2, 24 hours, and 14 days, the rats were euthanized, and both carotid arteries were processed for real-time polymerase chain reaction (2 hours), immunofluorescence and immunohistochemistry (24 hours), and morphometric analysis (14 days). ETS-1 mRNA was up regulated (2.4-fold) in injured carotid arteries. By immunofluorescence, we confirmed increased nuclear expression of ETS-1 24 hours postinjury. The carotid artery mRNA expression of monocyte chemotactic protein-1, cytokine-induced neutrophil chemoattractant-2, P-selectin, E-selectin, vascular cell adhesion molecule, and intercellular adhesion molecule was increased 2 hours after injury. ETS-1 DN but not ETS-1 MU significantly reduced mRNA and protein expression for monocyte chemotactic protein-1, P-selectin, and E-selectin in injured arteries. These changes were accompanied by concomitant reductions in vascular monocyte and leukocyte infiltration. Moreover, treatment with ETS-1 DN but not ETS-1 MU resulted in a 50% reduction in neointima formation at day 14 after balloon injury. This study unveils the role of ETS-1 as a mediator of inflammation and neointima formation in a model of carotid artery balloon injury and may result in the development of novel strategies in the treatment of vascular injury.
转录因子 ETS-1 是血管炎症和高血压中血管肥大的关键介质。我们测试了 ETS-1 是血管炎症反应和球囊损伤颈动脉后新生内膜增生的介质的假设。在这项研究中,我们利用了 ETS-1 显性负(DN)肽的可用性。将 Sprague-Dawley 大鼠分配到接受 ETS-1 DN、突变肽(ETS-1 MU)或载体(Veh)治疗,并接受颈动脉球囊损伤。在 2、24 小时和 14 天后,处死大鼠,并对双侧颈动脉进行实时聚合酶链反应(2 小时)、免疫荧光和免疫组化(24 小时)和形态计量分析(14 天)。损伤颈动脉中 ETS-1 mRNA 上调(2.4 倍)。通过免疫荧光,我们在损伤后 24 小时证实了 ETS-1 核表达增加。在损伤后 2 小时,颈动脉单核细胞趋化蛋白-1、细胞因子诱导的中性粒细胞趋化因子-2、P 选择素、E 选择素、血管细胞黏附分子和细胞间黏附分子的 mRNA 表达增加。ET-1 DN 但不是 ETS-1 MU 显著降低了损伤动脉中单核细胞趋化蛋白-1、P 选择素和 E 选择素的 mRNA 和蛋白表达。这些变化伴随着血管单核细胞和白细胞浸润的同时减少。此外,ET-1 DN 治疗但不是 ETS-1 MU 治疗导致球囊损伤后 14 天新生内膜形成减少 50%。这项研究揭示了 ETS-1 在颈动脉球囊损伤模型中作为炎症和新生内膜形成的介质的作用,并可能导致血管损伤治疗中新型策略的发展。